Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, octubre 06
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Amylyx Pharmaceuticals Inc
AMLX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$28.04
0.26
0.94%
Últ. Act.: Oct 6, 4:00 PM
$28.04
0.26
0.94%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Amylyx Pharmaceuticals Financials
Amylyx Pharmaceuticals (AMLX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
RAmylyx Pharma Q2 EPS $(0.39) Misses $(0.36) Estimate, Cash & Equivalents $279.8M. Cash runway Expected To Fund Operations Till 2028
Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 15.22 percent increase over losses of $(0.46) per share from
Benzinga Newsdesk
PRO
Amylyx Pharma Q1 EPS $(0.37), Inline, Cash, Cash Equivalents, And Short-Term Investments Were $279.8M, With Expected Cash Runway into 2028
Benzinga Newsdesk
PRO
Amylyx Pharma Q4 EPS $(0.30) Beats $(0.36) Estimate
Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.9 percent. This is a 45.45 percent increase over losses of $(0.55) per share from the
Benzinga Newsdesk
Earnings Scheduled For March 3, 2026
Benzinga Insights
A Look at Amylyx Pharma's Upcoming Earnings Report
Benzinga Insights
PRO
Amylyx Pharma Q3 EPS $(0.37) Beats $(0.45) Estimate
Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.45) by 17.04 percent. This is a 30.19 percent increase over losses of $(0.53) per share from the
Benzinga Newsdesk
